all report title image
  • Published On : Sep 2022
  • Code : CMI3018
  • Industry : Pharmaceutical
  • Pages : 167
  • Formats :

Bioactive peptides are amino acids combined together through a covalent bond. Bioactive peptides are extracted from various natural sources, such as soy, oat, and pulses (chickpea, beans, peas, and lentils) etc.  Thereby providing a variety of health benefits such as better cardiovascular, digestive, endocrine functioning, as well as the immune and nervous system. They are also used in protecting important contents of food and beverages, resulting in decreased oxidation and degradation of the products. Although these peptides are extracted from natural sources, some of them have been designed with the help of chemical synthesis.

Global bioactive peptide market is estimated to be valued at US$ 4,960.4 million in 2022 and is expected to exhibit a CAGR of 9.4% during the forecast period (2022-2030).

Figure 1. Global Bioactive Peptide Market Share (%), by Source, 2022

Bioactive Peptide  | Coherent Market Insights

Increasing preference of plant based collagen peptide and plant based alternatives for egg and seafood is expected to drive growth of the global bioactive peptide market over the forecast period.

Increasing preference and use of plant collagen peptide is expected to drive growth of the global bioactive peptide market over the forecast period. For instance, on June 29, 2022, Vital Proteins, manufactures of  health supplement Product Company, announced the launch of Vital Proteins Lemon Collagen Peptides, containing grass-fed, pasture-raised collagen with an added boost of lemon flavor.

Moreover, in October 2021, Nestle, a food company, announced the launch of plant based alternatives for egg and shrimp (Seafood). The egg alternative was launched under Garden Gourmet vEGGie, the product was vegan, contains soy protein and omega-3 fatty, whereas Nestle expanded its plant-based seafood offerings with the Garden Gourmet Vrimp, which was vegan and made from a combination of seaweed, peas and konjac root.

CMI table icon

Bioactive Peptide Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 4,960.4 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 9.4% 2030 Value Projection: US$ 10,149.9 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Source: Plant, Milk, Egg, Meat, Fish, Others (Bacterial Antimicrobial Peptides and Venom Peptidomics)
  • By Therapeutic Area: Antihypertensive, Antioxidant, Immunostimulatory, Antimicrobial, Diabetes, Others( Gastrointestinal System and Cardiovascular System)
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others(Drug Store and Mail-Order Pharmacy)
Companies covered:

Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd., Naturade, Royal DSM, MYOS RENS Technology Inc., Natural Factors Inc., Valio Oy, GenScript, HELIX BIOMEDIX, Oryn Therapeutics, Selecta Biosciences, NIBEC, vivitide, PEPTIDE INSTITUTE, INC, BCN Peptides, Setlance srl., APEPTICO Forschung und Entwicklung GmbH, and BIONANOPLUS.

Growth Drivers:
  • Increasing preference for plant based collagen peptide and plant based alternatives
  • Increasing number of inorganic strategies such as product launch by key players
Restraints & Challenges:
  • Increasing number of bioactive peptides alternatives
  • Lack of documented evidence of safety, lack of complete knowledge regarding the mechanism and functions of bioactive peptides.

Figure 2. Global Bioactive Peptide Market Share (%), by Region, 2022

Bioactive Peptide  | Coherent Market Insights

Increasing number of inorganic strategies such as product launch by key players in market is expected to drive growth of the global bioactive peptide market over the forecast period.

Increasing number of inorganic strategies such as product launch by market players is expected to boost the global bioactive peptide market growth over the forecast period. For instance, In November 2018, Nuritas Ltd., a biotechnology company, announced the commercial launch of Peptide which contained anti-inflammatory bioactive peptides. It was the first bioactive ingredient discovered and delivered through artificial intelligence.

Furthermore, in October 2020, Hofseth Biocare, a biotechnology company, announced the launch of ProGo bioactive peptides in the U.S., which helps maintain iron-rich blood, promotes energy utilization, supports red blood cell production, supports gastrointestinal and immune system health and assists in iron absorption from daily diet.

Global Bioactive Peptide Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

Increasing research and development by key players during the pandemic for the treatment of Covid-19 patients is expected to boost the bioactive peptide market growth. For instance, in April 2020, APEPTICO Forschung und Entwicklung GmbH, a biotechnology company, announced that it had signed, together with the solnatide consortium, the Grant Agreement with the European Commission to accelerate the process of making APEPTICO’s proprietary investigational medicinal product (IMP), Solnatide available for medical treatment of patients severely affected by the novel coronavirus 2019 (SARS-CoV-2) disease, COVID-19.

Thus, impact of the Coronavirus (COVID-19) pandemic had positive impact on the global bioactive peptide market during the pandemic.

Global Bioactive Peptide Market: Key Developments

Increasing research and development by key market players in the global bioactive peptide market is expected to drive the global bioactive peptide market over the forecast period. For instance, in September 2020, NeoMatrix Therapeutics, Inc., a clinical-stage company, announced positive topline data from its Phase 1 clinical trial of NMT-cP12, a bioactive peptide for intravenous treatment of burns within 2 to 4 hours of injury.

Furthermore, increasing number of inorganic strategies such as product launch by market players is expected to drive growth of the global bioactive peptide market over the forecast period. For instance, Rousselot, a collagen-based solutions, announced the launch of MSC-certified (Marine Stewardship Council) marine collagen peptides, Peptan, at Beauty & Skincare Formulation Conference 2021, which is made up of wild-caught marine white fish and certified by the Marine Stewardship Council (MSC) to help beauty and nutrition brands differentiate and expand their portfolio in nutria-cosmetics and dietary supplements.

Global Bioactive Peptide Market: Restraint

Increasing number of bioactive peptides alternatives is one of the major factors, which is expected to hamper growth of the global bioactive peptides market over the forecast period, Such as fungi, edible insects, marine macro algae and vegetable proteins.

Other major factor hindering the market growth is lack of documented evidence of safety, lack of complete knowledge regarding the mechanism and functions of bioactive peptides.

Key Players

Major players operating in the global bioactive peptide market include Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd., Naturade, Royal DSM, MYOS RENS Technology Inc., Natural Factors Inc., Valio Oy, GenScript, HELIX BIOMEDIX, Oryn Therapeutics, Selecta Biosciences, NIBEC, vivitide, PEPTIDE INSTITUTE, INC, BCN Peptides, Setlance srl., APEPTICO Forschung und Entwicklung GmbH, and BIONANOPLUS.

Bioactive peptides are a group of biological molecules that are normally buried in the structure of parent proteins and become active after the cleavage of the proteins. Another group of peptides is actively produced and found in many microorganisms. Many groups of bioactive peptides have been marketed chemically or recombinantly. The bioactive peptides are ingredients that provide nutritive value to the food by adding protein and other important nutrients. Bioactive peptides are gaining popularity, owing to health benefits such as prevention and control of chronic disease conditions like cardiovascular disease, diabetes, cancer, and infectious diseases. Therefore, bioactive peptides are used as treatment therapy for most of the functional disorders such as irritable bowel disease, which is expected to drive the market growth.

Market Dynamics

Increasing research and development by key market players for the treatment of pulmonary edema and rheumatoid arthritis is expected to drive growth of the global bioactive peptide market over the forecast period. For instance, on May 30, 2022, APEPTICO Forschung und Entwicklung GmbH, a biotechnology company, announced that the 3-D structure and the mechanism of action of Solnatide,( a dry powder inhalation and an inhaled aerosol formulation of a synthetic peptide) a possible treatment for pulmonary oedema, had been disclosed by an international network of scientists led by APEPTICO.

Similarly, in June 2021, Oryn Therapeutics, a clinical stage biotechnology company, had opened recruitment for rheumatoid arthritis patients for a Phase 1b clinical trial, which was a Randomized, Double-blind, Vehicle Controlled, and Repeat Dose Comparative Study in RA (rheumatoid arthritis) Patients Managed with DMARDs (Disease-modifying antirheumatic drugs), whereas the Phase 1a clinical trial study had been successfully completed in 2020.

Key features of the study:                                          

  • This report provides in-depth analysis of the global bioactive peptide market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 – 2030, considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global bioactive peptide market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd., Naturade, Royal DSM, MYOS RENS Technology Inc., Natural Factors Inc., Valio Oy, GenScript, HELIX BIOMEDIX, Oryn Therapeutics, Selecta Biosciences, NIBEC, vivitide, PEPTIDE INSTITUTE, INC, BCN Peptides, Setlance srl., APEPTICO Forschung und Entwicklung GmbH, and BIONANOPLUS
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global bioactive peptide market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global bioactive peptide market

Detailed Segmentation:

  • Global Bioactive Peptide Market, By Source:
    • Plant
    • Milk
    • Egg
    • Meat
    • Fish
    • Others (Bacterial Antimicrobial Peptides and Venom Peptidomics)
  • Global Bioactive Peptide Market, By Therapeutic Area:
    • Antihypertensive
    • Antioxidant
    • Immunostimulatory
    • Antimicrobial
    • Diabetes
    • Others( Gastrointestinal System and Cardiovascular System)
  • Global Bioactive Peptide Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others(Drug Store and Mail-Order Pharmacy)
  • Global Bioactive Peptide Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Europe
      • By Country
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Archer Daniels Midland Company*
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Seagarden AS
    • Phermpep Co. Ltd.
    • Arlak Biotech Pvt. Ltd.
    • Naturade
    • Royal DSMConsort Medical plc
    • MYOS RENS Technology Inc.
    • Natural Factors Inc.
    • Valio Oy
    • GenScript
    • HELIX BIOMEDIX
    • Oryn Therapeutics
    • Selecta Biosciences
    • NIBEC
    • vivitide
    • PEPTIDE INSTITUTE, INC
    • BCN Peptides
    • Setlance srl.
    • APEPTICO Forschung und Entwicklung GmbH
    • BIONANOPLUS

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global bioactive peptide market size is estimated to be valued at US$ 4,960.4 million in 2022 and is expected to exhibit a CAGR of 9.4% between 2022 and 2030.
Increasing preference of plant collagen peptide and plant based alternatives & increasing number of inorganic strategies such as product launch by the key players.
Plant is the leading source segment in the market.
The major factors hampering growth of the market include increasing number of bioactive peptides alternatives,  lack of documented evidence of safety, lack of complete knowledge regarding the mechanism and functions of bioactive peptides, 
Major players operating in the market include Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd., Naturade, Royal DSM, MYOS RENS Technology Inc., Natural Factors Inc., Valio Oy, GenScript, HELIX BIOMEDIX, Oryn Therapeutics, Selecta Biosciences, NIBEC, vivitide, PEPTIDE INSTITUTE, INC, BCN Peptides, Setlance srl., APEPTICO Forschung und Entwicklung GmbH and BIONANOPLUS.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo